Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma

The Committee for Medicinal Products for Human Use has recommended the approval of an indication extension for Johnson & Johnson's TALVEY (talquetamab) to treat adults with relapsed or refractory multiple myeloma. This recommendation could potentially expand the drug's use in earlier line treatments. The approval process is a significant step for JNJ as it seeks to enhance its portfolio in oncology.